Our Company
Aerogen Pharma is at the forefront of developing the first generation of inhaled drugs specifically designed for critical care
Aerogen Pharma is an Irish specialty pharmaceutical company with operations in Galway, Ireland, San Mateo, California, and Morrisville, North Carolina. We are the drug development arm of the Aerogen Group, the global market leader in high performance aerosol drug delivery. With industry-leading expertise, a proven track record in the development of inhalation therapeutics, and a technology platform based on patented enhancements to the global #1 hospital nebuliser product range, we are inspired to create a new standard for aerosol drug delivery to the lungs.
-1pplen.png){kind=spacer}
AeroFactTM - Phase 3 Development Program
The AeroFact Phase 3 development program is assessing an investigational, non-invasive pulmonary surfactant treatment for respiratory distress syndrome in preterm infants. The investigational program’s goals include the following:
Demonstrating the ability to reduce the risk of complications caused by the current standard of care - invasive surfactant administration requiring intubation of the preterm infant
Minimising interruption in nCPAP or non-invasive ventilation during surfactant delivery
Minimising patient discomfort
Get in touch
To engage us on our technology, product pipeline,
clinical trials or partnerships, please provide
a few details below and we’ll have the right
Aerogen Pharma representative get in touch.